Nilsine Partners LLC Sells 2,496 Shares of Astrazeneca Plc $AZN

Nilsine Partners LLC lessened its holdings in shares of Astrazeneca Plc (NYSE:AZN) by 28.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 6,177 shares of the company’s stock after selling 2,496 shares during the quarter. Nilsine Partners LLC’s holdings in Astrazeneca were worth $568,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of AZN. Binnacle Investments Inc boosted its stake in shares of Astrazeneca by 21.8% during the 3rd quarter. Binnacle Investments Inc now owns 660 shares of the company’s stock worth $51,000 after acquiring an additional 118 shares during the period. Chapin Davis Inc. increased its holdings in shares of Astrazeneca by 3.3% during the 3rd quarter. Chapin Davis Inc. now owns 3,795 shares of the company’s stock worth $291,000 after acquiring an additional 120 shares during the last quarter. 44 Wealth Management LLC raised its stake in Astrazeneca by 0.7% in the 3rd quarter. 44 Wealth Management LLC now owns 16,722 shares of the company’s stock valued at $1,283,000 after acquiring an additional 124 shares during the period. CoreCap Advisors LLC raised its stake in Astrazeneca by 30.6% in the 3rd quarter. CoreCap Advisors LLC now owns 534 shares of the company’s stock valued at $41,000 after acquiring an additional 125 shares during the period. Finally, Highline Wealth Partners LLC lifted its holdings in Astrazeneca by 32.0% during the 3rd quarter. Highline Wealth Partners LLC now owns 532 shares of the company’s stock valued at $41,000 after purchasing an additional 129 shares during the last quarter. Institutional investors own 20.35% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on the stock. HSBC reaffirmed a “buy” rating and set a $108.00 price objective on shares of Astrazeneca in a research report on Wednesday, December 10th. TD Cowen restated a “buy” rating on shares of Astrazeneca in a research note on Wednesday, March 18th. Weiss Ratings started coverage on shares of Astrazeneca in a report on Wednesday, March 11th. They set a “buy (b)” rating for the company. Wall Street Zen upgraded shares of Astrazeneca from a “hold” rating to a “buy” rating in a research note on Friday, March 20th. Finally, Deutsche Bank Aktiengesellschaft reissued a “sell” rating on shares of Astrazeneca in a report on Friday, February 6th. Nine investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $95.75.

Astrazeneca Price Performance

Shares of NYSE AZN opened at $203.32 on Friday. Astrazeneca Plc has a 12 month low of $122.48 and a 12 month high of $212.71. The company has a debt-to-equity ratio of 0.51, a current ratio of 0.94 and a quick ratio of 0.72. The stock has a market cap of $315.33 billion, a price-to-earnings ratio of 31.04, a price-to-earnings-growth ratio of 1.51 and a beta of 0.35.

Astrazeneca Announces Dividend

The business also recently declared a dividend, which was paid on Monday, March 23rd. Stockholders of record on Friday, February 20th were issued a dividend of $1.595 per share. The ex-dividend date was Friday, February 20th. This represents a dividend yield of 156.0%. Astrazeneca’s dividend payout ratio is 66.26%.

More Astrazeneca News

Here are the key news stories impacting Astrazeneca this week:

• Positive Sentiment: Late‑stage liver cancer combo with Imfinzi showed a meaningful improvement in progression‑free survival, strengthening AstraZeneca’s oncology franchise and near‑term commercial/pipeline value. Article Title
• Positive Sentiment: Guggenheim raised its price target (to 16,500 GBp) and reiterated a Buy, a supportive broker call that can help investor sentiment and valuation narratives. Article Title
• Positive Sentiment: Bank analysis views efzimfotase alfa (HPP program) as potentially worth $2.6bn with upside to $4.4bn despite mixed adult results, supporting revenue expectations if regulatory filings proceed. Article Title
• Neutral Sentiment: Efzimfotase alfa phase‑3 readouts are mixed — strong pediatric results but a missed primary endpoint in adults — and AstraZeneca plans to pursue regulatory submissions based on the totality of data and unmet need; this creates clinical and commercial uncertainty until regulators weigh in. Article Title
• Neutral Sentiment: Market note: coverage and headlines (including Zacks) reflect a modest intraday move higher, showing investor attention but not a decisive trend change. Article Title
• Negative Sentiment: Deutsche Bank reaffirmed a Sell rating with a low £115 target, a contrasting bearish analyst view that could pressure sentiment if other downgrades follow. Article Title
• Negative Sentiment: U.S. policy risk: a proposed Trump administration tariff proposal (up to 100% on branded drugs) raises potential pricing and margin risk for multinationals; carve‑outs exist for companies that commit to U.S. manufacturing or pricing deals, but the announcement increases regulatory uncertainty. Article Title

About Astrazeneca

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.